Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Colorectal Neoplasms 2Untreated Resectable Pancreatic Adenocarcinoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Pancreatic Ductal Adenocarcinoma 1Osteosarcoma 1Melanoma 1Glioma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

X-Rays 4Phantoms, Imaging 4Nuclear Medicine Department, Hospital 4Magnetic Resonance Spectroscopy 4regorafenib 3Specimen Handling 3Nivolumab 3Cyclophosphamide 3Biopsy 3ulixertinib 2tipifarnib 2selpercatinib 2pembrolizumab 2olaparib 2larotrectinib 2ivosidenib 2fludarabine 2ensartinib 2cabozantinib 2Etoposide 2Docetaxel 2tocilizumab 1tazemetostat 1poly ICLC 1palbociclib 1naxitamab 1mifamurtide 1humanized 3F8 anti-GD2 monoclonal antibody 1glucarpidase 1gamma-Glutamyl Hydrolase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Osteosarcoma × Hydroxychloroquine × Clear all
NCT03598595 2026-05-14

Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
31 enrolled
Sarcoma

Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡